Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 8:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 35 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Ocular Discomfort Clear all
Terminated Phase 4 Interventional Results available

Does Topical Ophthalmic Anesthetic Prior to Probing and Irrigation Decrease Pain?

NCT04229771
View directory record Official record
Conditions
Epiphora, Dacryostenosis, Dacryocystitis
Interventions
Proparacaine Hydrochloride ophthalmic solution, USP 0.5%, Balanced salt solution
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Oct 24, 2026, 8:20 PM EDT
Completed Phase 2 Interventional

Prolongation of Contact Lens Comfortable Wear Duration by CLM2 Topical Gel

NCT03994406
View directory record Official record
Conditions
Contact Lens Discomfort, Contact Lens-induced Corneal Disorder, Contact Lens Acute Red Eye, Contact Lens-induced Corneal Fluorescein Staining
Interventions
CLM2 topical gel, Placebo topical gel
Drug
Lead sponsor
Glia, LLC
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2023 · Synced Oct 24, 2026, 8:20 PM EDT
Completed Not applicable Interventional Results available

Pilot Study for Investigating the Effect of the Bruder Eye Hydrating Compress on Contact Lens Discomfort in Contact Lens Wearers

NCT02848222
View directory record Official record
Conditions
Contact Lens Discomfort, Dry Eye Disease, Meibomian Gland Dysfunction
Interventions
Bruder Moist Heat Compress, Washcloth
Device · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Oct 24, 2026, 8:20 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of Anti-Inflammatory Treatment in Dry Eye Patients

NCT01276223
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Difluprednate 0.05% ophthalmic emulsion, Difluprednate vehicle
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
722 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2013 · Synced Oct 24, 2026, 8:20 PM EDT
Terminated Phase 4 Interventional

Intracanalicular Dexamethasone Insert for the Treatment of Inflammation and Discomfort in Dry Eye Disease (DEcIDED)

NCT04527887
View directory record Official record
Conditions
Dry Eye
Interventions
Dextenza (IDI) (Sustained Release Dexamethasone), (0.4 mg), ProLong™ collagen plugs
Drug · Other
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 24, 2026, 8:20 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease

NCT02188160
View directory record Official record
Conditions
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Interventions
KPI-121, Placebo
Drug
Lead sponsor
Kala Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
11
States / cities
Artesia, California • Mission Hills, California • Rancho Cordova, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Oct 24, 2026, 8:20 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease

NCT02819284
View directory record Official record
Conditions
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Interventions
KPI-121 0.25% Ophthalmic Suspension, Vehicle of KPI-121 0.25% Ophthalmic Suspension
Drug
Lead sponsor
Kala Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
909 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
62
States / cities
Birmingham, Alabama • Chandler, Arizona • Jonesboro, Arkansas + 54 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 24, 2026, 8:20 PM EDT
Completed Not applicable Interventional Results available

Comparison of Patient Comfort After Two Anesthetic Protocols for Injections Into the Eye

NCT01087489
View directory record Official record
Conditions
Pain
Interventions
4% lidocaine, 3.5% ophthalmic lidocaine gel
Drug
Lead sponsor
Miami VA Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 20, 2012 · Synced Oct 24, 2026, 8:20 PM EDT
Completed Not applicable Interventional Results available

Tangible Hydra-PEG: A Promising Solution for Scleral Lens Wearers With Dry Eye

NCT03417505
View directory record Official record
Conditions
Dry Eye, Dry Eye Syndromes
Interventions
Scleral lenses treated with Tangible Hydra-PEG, Untreated scleral lenses
Device
Lead sponsor
Tangible Science
Industry
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Sacramento, California • Fort Lauderdale, Florida • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 24, 2026, 8:20 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Systane Complete for the Treatment of Contact Lens Discomfort

NCT03682809
View directory record Official record
Conditions
Contact Lens Discomfort, Dry Eye
Interventions
Systane Complete
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Birmingham, Alabama • Babylon, New York • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 6, 2020 · Synced Oct 24, 2026, 8:20 PM EDT
Recruiting Phase 4 Interventional

Ocular Surface Health and Tear Film Stability With a Nasal Spray Dry Eye Treatment

NCT07606625
View directory record Official record
Conditions
Dry Eye, Meibomian Gland Dysfunction
Interventions
Varenicline 0.03Mg/Spray Nasal Soln
Drug
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 24, 2026, 8:20 PM EDT
Terminated Phase 4 Interventional Results available

Effects of Supplementation With PUFAs and Antioxidants for Contact Lens Discomfort

NCT04163328
View directory record Official record
Conditions
Dry Eye, Contact Lens Complication
Interventions
HydroEye®
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 24, 2026, 8:20 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Lifitegrast 5% Ophthalmic Solution and Contact Lens Dryness

NCT03686878
View directory record Official record
Conditions
Contact Lens, Contact Lens Discomfort, Contact Lens Dryness
Interventions
Lifitegrast
Drug
Lead sponsor
EV Clinical Trials
Other
Eligibility
21 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2018 · Synced Oct 24, 2026, 8:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Laser Vision Correction Use of an Eye Shield for Maintaining Vision and Mitigating Pain

NCT01675375
View directory record Official record
Conditions
Post Laser Vision Correction Pain and Discomfort
Interventions
Eye Shield
Device
Lead sponsor
FORSIGHT Vision3
Industry
Eligibility
18 Years to 60 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
5
States / cities
San Diego, California • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2013 · Synced Oct 24, 2026, 8:20 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Topical Fibrinogen-Depleted Human Platelet Lysate in Patients With Dry Eye Secondary to Graft vs. Host Disease

NCT03414645
View directory record Official record
Conditions
Dry Eye, Graft-versus-host-disease, Ocular Discomfort
Interventions
CAM-101 10%, Vehicle Control, CAM-101 30%
Biological
Lead sponsor
Cambium Bio Limited
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Palo Alto, California • Boston, Massachusetts • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 24, 2026, 8:20 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications

NCT04354545
View directory record Official record
Conditions
Glaucoma, Ocular Surface Disease
Interventions
Xiidra (Lifitegrast ophthalmic solution) 5%
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Fountain Valley, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 24, 2026, 8:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Meibomian Gland Dysfunction Management With ZEST Protocol

NCT03968731
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Dry Eye Syndromes, Ocular Surface Disease
Interventions
Zocular Eyelid System Treatment
Other
Lead sponsor
University of the Incarnate Word
Other
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2022 · Synced Oct 24, 2026, 8:20 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Treating Contact Lens Discomfort With Varenicline Solution Nasal Spray 0.03mg

NCT07705893
View directory record Official record
Conditions
Dry Eye
Interventions
Tyrvaya
Drug
Lead sponsor
Ocular Aesthetics, LLC dba Ocular Clinical Trials
Other
Eligibility
18 Years to 99 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 24, 2026, 8:20 PM EDT
Recruiting Phase 2 Interventional

An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease

NCT07503886
View directory record Official record
Conditions
Dry Eye Disease (DED)
Interventions
DFL24498, Vehicle
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
24
States / cities
Chandler, Arizona • Azusa, California • Glendale, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 24, 2026, 8:20 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease

NCT02813265
View directory record Official record
Conditions
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Interventions
KPI-121 0.25% Ophthalmic Suspension, Vehicle of KPI-121 0.25% Ophthalmic Suspension
Drug
Lead sponsor
Kala Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
918 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
60
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 53 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 24, 2026, 8:20 PM EDT
Completed Phase 3 Interventional

Patient Assessment of Topical Anesthetic Effectiveness for Intravitreal Injections

NCT01027611
View directory record Official record
Conditions
Pain
Interventions
proparacaine HCL 0.5%, proparacaine HCL 0.5% + 4% lidocaine solution, 3.5% viscous lidocaine gel
Drug
Lead sponsor
Illinois Retina Associates
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Joliet, Illinois
Source: ClinicalTrials.gov public record
Updated May 4, 2010 · Synced Oct 24, 2026, 8:20 PM EDT
Withdrawn Phase 4 Interventional

Use of 5.0% Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Disease in Contact Lens Wearers

NCT03431272
View directory record Official record
Conditions
Contact Lens Dry Eye
Interventions
Lifitegrast
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 25, 2018 · Synced Oct 24, 2026, 8:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Treating Contact Lens Discomfort With Orthokeratology

NCT03566680
View directory record Official record
Conditions
Dry Eye, Contact Lens Complication
Interventions
Orthokeratology
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 45 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Oct 24, 2026, 8:20 PM EDT
Recruiting Phase 4 Interventional

Does Topical Ophthalmic Proparacaine 0.5% Prior to Probing and Irrigation Decrease Pain?

NCT05663684
View directory record Official record
Conditions
Epiphora, Dacryostenosis, Dacryocystitis
Interventions
Proparacaine Hydrochloride ophthalmic solution, USP 0.5%, Balanced salt solution
Drug
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 23, 2022 · Synced Oct 24, 2026, 8:20 PM EDT